Guldager B, Jelnes R, Jørgensen S J, Nielsen J S, Klaerke A, Mogensen K, Larsen K E, Reimer E, Holm J, Ottesen S
Department of Surgery, Central Hospital Hillerød, Denmark.
J Intern Med. 1992 Mar;231(3):261-7. doi: 10.1111/j.1365-2796.1992.tb00533.x.
A double-blind, randomized multicentre study was undertaken to evaluate the possible effect of chelation treatment with ethylenediamine-tetraacetic acid (EDTA) in patients with severe intermittent claudication. A total of 153 patients received 20 intravenous infusions of either 3 g Na2EDTA or placebo during a period of 5-9 weeks. Vitamin, mineral and trace element supplements were administered orally. The changes observed in the pain-free and maximal walking distances, measured on a treadmill, were similar in the two groups. During the 3-month (n = 149) and 6-month (n = 123) follow-up period, no long-term therapeutic effect of EDTA could be demonstrated. The ankle-brachial blood pressure index remained unchanged throughout the study period. This study failed to demonstrate any effect of EDTA chelation treatment in intermittent claudication.
开展了一项双盲、随机多中心研究,以评估乙二胺四乙酸(EDTA)螯合疗法对重度间歇性跛行患者可能产生的影响。共有153例患者在5至9周内接受了20次静脉输注,分别为3g Na2EDTA或安慰剂。口服维生素、矿物质和微量元素补充剂。两组在跑步机上测量的无痛行走距离和最大行走距离的变化相似。在3个月(n = 149)和6个月(n = 123)的随访期内,未发现EDTA有长期治疗效果。整个研究期间,踝臂血压指数保持不变。本研究未能证明EDTA螯合疗法对间歇性跛行有任何效果。